Skip to Content Skip to Search
GSK Pakistan Sykes Building
GSK Pakistan

Sykes Building

GSK in Pakistan

GlaxoSmithKline Pakistan Limited

GSK is a long-established investor in Pakistan. Our legacy company GlaxoLaboratories Pakistan Ltd. was the first pharmaceutical company to be listed on the Karachi Stock Exchange in 1951.

As a highly agile and committed team, we are passionately building on our 70-year legacy of indisputable industry volume leadership, providing trusted quality medicines and vaccines, to more than 200 million patients across Pakistan.

We aspire to capitalize on our leadership position by growing our general medicines portfolio, introducing innovative therapies, using digital solutions, and always doing the right thing.

GSK Pakistan caters to many therapy areas which include Anti-infectives, Respiratory, Dermatology, Analgesics, Urology, Allergy, Central Nervous System, Vitamins and Vaccines.

We aim to consistently produce and improve access to quality medicines to help improve the quality of patients’ lives. Our key pharmaceutical brands include Augmentin, Ventolin, Amoxil, Velosef, Dermovate, Betnovate, Clobevate and Calpol.

GSK also has a strong presence in the national Expanded Program on Immunization (EPI), with its Rotavirus Gastroenteritis vaccine (RVGE). Rotavirus Gastroenteritis is attributed to be one of main causes for mortality in children under the age of 5 and since its introduction in 2016 and approximately 39 million doses have been supplied, protecting around 17.5 million babies across the country.

Today GSK stands as the pharma market leader in Pakistan with a volume share of almost 12%. Through the successfully integration of BMS, UCB, Novartis Vaccines, and Stiefel over the years, GSK Pakistan has grown into a highly diverse and profitable business that now boasts 115 brands and 270 registered products.

Major competitors are multinational pharmaceutical companies such as Abbott, Novartis, Pfizer, Sanofi Aventis, and Getz, Sami, Searle, Bosch and Barrett Hodgson amongst local companies.

GSK Pakistan presently employs almost 1,900 persons across its manufacturing, pharmaceutical and sales functions. Our Pharma Supply Chain (PSC) division, which manufactures 400 million packs anually, consists of three facilities, all of which are situated in Karachi at West Wharf, F-268 SITE and Korangi.

PSC, F-268, S.I.T.E., Karachi

The F-268 facility is located in the Sindh Industrial Trading Estate (SITE) and is the largest pharma facility in Pakistan. Featuring advanced Digital Data Analytics tools, it has has three primary manufacturing sections – Liquids Block, Tablets Block, and a dedicated Penicillin Block. This site also has a small dedicated unit for Iodex Cream. Over 115 SKUs are manufactured at this site, with an annual volume of around 220 million packs. Major products manufactured at this site are Augmentin (in Dessiflex blister packing), Amoxil, Calpol, Thyroxin, Angised and Lanoxin. The site has also launched CRSF (child resistant senior friendly) packaging for some of its SKUs recently. 

PSC, Korangi, Karachi

Located in the Korangi Industrial Area, this state of the art manufacturing site has a dedicated block for Cephalosporins, both oral and injectable, a sterile facility for liquid ampoules and a unit for tablets. The site manufactures around 77 SKUs and produces an annual volume of around 45 million packs. Major products manufactured at this site are Velosef, Capotin, Fortum, Ceporex, Zinacef and Theragran Ultra.

PSC, West Wharf, Karachi

GSK West Wharf is a pioneering pharmaceutical manufacturing facility that is  located on the sea shore close to the Karachi Port area and city commercial centre. The wide range of products manufactured at this site include Topicals, Ophthalmics, Otics Drops and Spansules Betnovate, Dermovate and Fefol Vit feature among key products. 68 Stock Keeping Units (SKUs) are manufactured here, with an annual volume of around 150 million packs.